SYK$373.135
Chart
Performance
Key Stats
AI SYK Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyStryker Corporation exhibits strong fundamental performance and positive thematic alignment, supported by consistent growth and profitability. Technical indicators suggest a recent pullback but maintain an overall bullish long-term outlook. The company is well-positioned for continued success in the medical technology sector.
Thematic
Stryker operates in the resilient and growing medical technology sector, benefiting from demographic trends, technological advancements in healthcare, and increasing demand for innovative medical devices. Its focus on orthopaedics, surgical equipment, and neurotechnology positions it well within these growth areas.
Fundamental
Stryker demonstrates robust financial health with solid revenue and earnings growth, strong profitability, and a well-managed balance sheet. Its consistent dividend payments also indicate financial stability.
Technical
Stryker's stock has experienced a recent decline but remains in a long-term uptrend. Key technical indicators suggest potential near-term consolidation or a bounce from current levels.
| Factor | Score |
|---|---|
| Healthcare Demographics | 90 |
| Medical Technology Innovation | 85 |
| Growth in Minimally Invasive Surgery | 88 |
| Healthcare Spending & Reimbursement | 70 |
| Emerging Market Penetration | 75 |
| Factor | Score |
|---|---|
| Valuation | 50 |
| Profitability | 85 |
| Growth | 88 |
| Balance Sheet Health | 80 |
| Cash Flow | 85 |
| Dividend Yield | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 55 |
| Momentum | 65 |
| Volume Analysis | 70 |
| Support and Resistance | 75 |
| Short-Term Trading Signals | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Consistent EPS Surprises
Stryker Corporation (SYK) has consistently exceeded earnings per share (EPS) estimates for the past several quarters, with the latest quarter showing a positive surprise of 5.23% (reported $2.84 vs. estimate $2.70). This trend indicates robust operational execution and potentially underappreciated profitability.
Positive Revenue Trends
While specific recent quarterly revenue figures are not directly provided, the annual revenue for 2024 is projected to be $22.595 billion, an increase from $20.498 billion in 2023. This signifies continued top-line growth for the company.
Bearish Points (7)
High Trailing P/E Ratio
The trailing P/E ratio of 53.46 is significantly higher than many industry averages, potentially indicating that the stock is overvalued. Investors should scrutinize future growth prospects to justify this valuation.
Fluctuating Net Margins
While annual net margins have shown improvement from 11.7% in 2021 to 13.2% in 2024, quarterly net margins can be more volatile. For example, Q4 2024 showed a net margin of 8.5%, a considerable dip from Q3 2024's 15.2%. This suggests potential near-term margin pressures.
Calendar
June 2025
30
Ex-Dividend Date
July 2025
31
Next Dividend Date
August 2025
1
Next Earnings Date
H: $3.15
A: $3.07
L: $3.00
H: 6.09B
A: 5.93B
L: 5.79B
Profile
Stryker Corporation operates as a medical technology company. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke, cranial, and maxillofacial and chest wall devices, as well as dural substitutes and sealants; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries; thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Seasonals
Price Target
423.06 USD
The 39 analysts offering 1 year price forecasts for SYK have a max estimate of 465.00 and a min estimate of 306.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
A direct and primary competitor to Stryker in the orthopedic market, specializing in joint replacement (hip, knee), trauma, spine, and dental implants.
Weight: 98
Its DePuy Synthes division is a major global competitor in orthopedics, surgical technologies, and neurosurgical solutions, overlapping significantly with Stryker's core segments.
Weight: 95
A broad medical technology leader with substantial overlap in surgical instruments, neurovascular devices, spine, and cardiovascular products, competing across multiple Stryker segments.
Weight: 90
A key global competitor in orthopedics (joint reconstruction, trauma), sports medicine, and advanced wound management, directly competing with Stryker's orthopedic and surgical solutions.